Abstract

OBJECTIVE: We evaluated the effect of terazosin in the improvement of lower urinary tract symptoms and flank pain in patients with internal ureteral stents.

METHODS: In this double-blind randomized clinical trial, 73 patients with unilateral ureteral stone and hydroureteronephrosis who underwent insertion of an internal ureteral stent after transureteral lithotripsy (TUL) were randomized into two groups. 37 patients received terazosin 2 mg (once nightly) for 4 weeks and 36 patients received placebo for the same time duration. After 4 weeks, all patients were asked about the incidence of frequency, nocturia and urgency by an International Prostate Symptom Score (IPSS) questionnaire, flank pain and pain during urination by a visual analog scale (VAS) score, and hematuria.

RESULTS: The mean VAS score was 2.21 in the terazosin group compared with 4.93 in the control group (p < 0.001). Nearly all the patients in the placebo group reported flank pain during urination but this was only reported in 54.5% of the patients in the terazosin group (p < 0.001). All criteria measured by the IPSS in the terazosin group were significantly lower than those in the placebo group (p = 0.0001).

CONCLUSIONS: Administration of terazosin for patients with an internal ureteral stent relieved some stent-related symptoms such as flank pain, pain during voiding, frequency, nocturia and urgency, but had no effect on hematuria.

Kommentare
1

The report confirms previous observations that α-receptor antagonists (in this study: terazosin) decrease pain experience in patients with ureteral stents. In addition it was observed that other discomfort such as frequency, urgency and nocturia were significantly higher in then placebo-treated group.

The report confirms previous observations that α-receptor antagonists (in this study: terazosin) decrease pain experience in patients with ureteral stents. In addition it was observed that other discomfort such as frequency, urgency and nocturia were significantly higher in then placebo-treated group.
Hans-Göran Tiselius